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p16 Protein, the product of the CDKN2/MTS1 gene, inhibits
cyclin-dependent kinase (cdk) 4- and cdk6-mediated phosphoryl-
ation of retinoblastoma (Rb) protein (Serrano et al, 1993; Hannon
and Beach, 1994). Both p16 and Rb proteins, which, like p53
protein, regulate cell cycle progression at the G1 checkpoint, func-
tion in a single regulatory pathway of the cell cycle and tumour
suppression (Serrano et al, 1993; Lukas et al, 1995), a conclusion
supported by the findings of inverse correlations between alter-
ation of both proteins in several types of cancer, including non-
small-cell lung cancers (NSCLCs) (Okamoto et al, 1994; Otterson
et al, 1994; Tam et al, 1994; Geradts et al, 1995; Kelley et al, 1995;
Shapiro et al, 1995).
It has been shown in NSCLCs that homozygous deletion and
DNA methylation are common mechanisms of CDKN2/MTS1
gene inactivation (Cairns et al, 1994; Hayashi et al, 1994;
Nakagawa et al, 1995; Okamoto et al, 1995; Otterson et al, 1995;
Shapiro et al, 1995) and that mutations of the gene are mostly
restricted to metastatic sites (Nakagawa et al, 1995; Okamoto et al,
1995). In a previous study (Kinoshita et al, 1996), we demon-
strated that immunohistochemical analysis of p16 protein in
tumour cells, using admixed stromal cells retaining normal p16
expression as an internal control, was a sensitive and suitable
method to screen for CDKN2 gene inactivation in NSCLCs.
Similarly, most Rb gene alterations result in the loss of Rb protein
expression or in a truncated Rb protein, which does not enter the
nucleus. Heterogeneous positive nuclear Rb immunostaining is,
in general, indicative of normal Rb function, whereas negative
intranuclear Rb immunostaining in all tumour cells reflects func-
tional loss of the Rb gene (Xu et al, 1991a, 1991b). Moreover, to
date, the presence or absence of normal Rb protein expression
determined by immunohistochemistry has been found to be the
most sensitive and specific method to examine Rb status in a given
tumour (Zhang et al, 1994).
Using the same cohort as the present study, we have previously
reported the reciprocal losses of p16 and Rb proteins and the
potential synergistic effect of the altered p16/Rb (p16 protein in
combination with Rb protein) pathway with altered p53 protein on
the proliferative activity in NSCLCs (Kinoshita et al, 1996). We
have also reported that Rb protein status alone was not a predictor
of survival and prognosis in a different cohort of NSCLC patients
(Dosaka-Akita et al, 1997). The prognostic value of p16 alter-
ations in NSCLCs has been reported only in a few studies (Kelley
et al, 1995; Kratzke et al, 1996; Taga et al, 1997), and is still
controversial. Moreover, no studies have clearly shown the impor-
tance of p16/Rb protein status for the clinical outcome of patients
with NSCLCs, although both p16 and Rb proteins are involved in
a single regulatory pathway of the cell cycle and tumour suppres-
sion, and are reciprocally lost in NSCLCs.
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Summary The predictive value of expression of p16INK4A, retinoblastoma (Rb) and p53 proteins for prognosis was evaluated in 76 patients
with non-small-cell lung cancers (NSCLCs) that were potentially curatively resected between 1990 and 1995, using the results of
immunostaining analyses of these proteins as reported in our previous study (Kinoshita et al, 1996). Of these NSCLCs, 22 (29%) lacked p16
protein expression and eight (11%) Rb protein, while 30 (39%) showed positive (altered) p53 protein expression. Survival of patients with p16-
negative tumours was not significantly different from that of patients with p16-positive tumours (5-year survival rates 67% and 72%
respectively, P = 0.8), nor was survival of patients with Rb-negative tumours significantly different from that of patients with Rb-positive
tumours (5-year survival rates 42% and 69% respectively, P = 0.9). Moreover, survival of patients with p16/Rb-negative (either p16- or Rb-
negative) tumours was not significantly different from that of patients with p16/Rb-positive (both p16- and Rb-positive) tumours (5-year
survival rates 67% and 68% respectively, P = 0.7). In contrast, survival of patients with p53-positive (altered) tumours tended to be shorter
than that of patients with p53-negative (unaltered) tumours (5-year survival rates 56% and 78% respectively, P = 0.06). In univariate analysis
of potential prognostic factors, p16, Rb and p16/Rb proteins were not significant prognostic factors in the present cohort of potentially
curatively resected NSCLCs. Altered p53 protein status tended to be a negative prognostic factor (P = 0.06 by the univariate analysis). These
results indicate that loss of p16 protein alone, or in combination with loss of Rb protein, does not predict the clinical outcome of patients with
resected NSCLCs. © 1999 Cancer Research Campaign
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In the present study, we investigated the prognostic significance
of p16, Rb and p16/Rb protein status determined by immunohisto-
chemistry in patients with resected NSCLCs.
MATERIALS AND METHODS
Patients and survival data
Of 111 NSCLCs studied in our previous report (Kinoshita et al,
1996), 92 tumours were resected with curative intent. Survival was
analysed in the present study for the 76 patients who met the
following criteria: (1) survived for more than 3 months after
surgery; (2) did not die of causes other than lung cancer within 5
years after surgery; and (3) were followed for more than 2 years
after surgery (for patients who remained alive). Twelve patients
who did not meet the above criteria were excluded from the present
study. Of the 12 patients, two died within 3 months after surgical
resection, five died of causes other than lung cancer within 5 years
after surgery, and five were followed up for no more than 2 years
after surgery. Four patients for whom no survival records after
surgery were obtained were also excluded from the present study.
Of the 76 patients analysed for survival, 54 were men and 22 were
women. Age and tobacco consumption at time of surgery (mean ±
standard deviation (s.d.) were 62.4 ± 8.8 years and 38.8 ± 33.5 pack
years respectively. Fifty-eight were still alive after surgery with a
median follow-up of 51 months (range 25–76). According to the
1981 WHO classification (WHO, 1982), tumour specimens were
histopathologically diagnosed as adenocarcinoma (n = 50), squa-
mous cell carcinoma (n = 21) and large-cell carcinoma (n = 5).
They represented 51 stage I, nine stage II and 16 stage IIIa tumours.
The post-surgical pathological TNM stage (pTNM) was deter-
mined according to the guidelines of the American Joint
Committee on Cancer (Beahrs et al, 1992). Twenty-four patients
received combination chemotherapy as post-surgical treatment.
Radiation therapy was not performed before or after surgery for any
patient. Because all the patients enrolled in the current study were
coded, they could not be individually identified.
Immunohistochemistry for p16, Rb, and p53 proteins
For the p16, Rb and p53 protein staining, the slides and results that
were previously reported (Kinoshita et al, 1996) were used for the
present study. The methods for staining of the p16, Rb, and p53
nuclear proteins of tumour cells have been described (Kinoshita et
al, 1996). Briefly, tumours from the primary NSCLCs were snap-
frozen in liquid nitrogen and stored at –80°C until use. Antibodies
used for immunohistochemistry of p16, Rb, and p53 proteins were
rabbit polyclonal anti-entire-human p16 antibodies (PharMingen,
San Diego, CA, USA), and mouse monoclonal antibodies PMG3-
245 (PharMingen) and PAb1801 (Oncogene Science, Manhasset,
NY, USA) respectively. Immunostaining was performed by the
biotin-streptavidin immunoperoxidase method with 3,3¢-diamino-
benzidine as a chromogen (SAB-PO kit, Nichirei, Tokyo, Japan).
Methyl green was used for counterstaining.
The criteria for the evaluation of p16, Rb, and p53 proteins have
been described previously (Xu et al, 1991; Dosaka-Akita et al,
1994, 1997; Kinoshita et al, 1996). Briefly, tumours were scored
as p16-negative (p16–) or Rb-negative (Rb–) if all malignant cells
Table 1 p16 and p16/Rb protein expression in 76 resected NSCLCs
p16 protein status p16/Rb protein status
Characteristics (+) (–) Pa (+)b (–)c Pa
54 (71%) 22 (29%) 46 (61%) 30 (39%)
Age (mean ± s.d.) 62.6 ± 8.5 61.9 ± 9.6 0.7 62.4 ± 8.8 62.4 ± 9.0 1.0
Gender
Male 40 14 0.4 35 19 0.2
Female 14 8 11 11
Smoking (pack years)
0–19 16 9 0.3 15 10 0.9
³20 38 13 31 20
Histological typed
Squamous 18 3 0.01 16 5 0.06
Non-squamous 36 19 30 25
pStage
I 34 17 0.5 30 21 0.9
II 7 2 6 3
IIIa 13 3 10 6
Chemotherapye
(–) 36 16 0.6 32 20 0.8
(+) 18 6 14 10
Rb
(+) 46 22 0.06
(–) 8 0
p53
(–) 35 11 0.2 32 14 0.046
(+) 19 11 14 16
aThe associations between loss of p16 and p16/Rb proteins and characteristics of patients except for age were analysed by c2 test (age
analysed by Student’s t-test). b(+), retaining both p16 and Rb proteins. c(–), lacking either p16 or Rb protein. dSquamous, squamous cell
carcinoma; Non-squamous, non-squamous cell carcinoma, including adenocarcinoma and large-cell carcinoma. eChemotherapy, post-surgical
chemotherapy.698 F Hommura et al
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had no nuclear staining, but surrounding normal stromal cells
showed adequate nuclear staining for p16 or Rb protein, respec-
tively, as positive internal controls. Tumours were regarded as
p16-positive (p16+) or Rb-positive (Rb+) if any malignant cell had
nuclear staining for p16 or Rb protein respectively. Tumours were
considered to be p53 alteration-positive (altered) (p53+) and thus
to contain putative p53 gene mutations when more than 10% of
tumour cells showed nuclear staining for p53 protein, and were
scored as p53 alteration-negative (unaltered) (p53–) in the other
cases.
Statistical analysis
The associations between losses of p16, Rb, p16/Rb and p53
proteins and various characteristics of patients and tumours were
analysed by the c2 test. Those between losses of p16, Rb, p16/Rb
and p53 proteins and age were analysed by Student’s t-test.
Survival curves of patients with tumours having different p16
and/or Rb protein status were estimated using the Kaplan–Meier
method (Kaplan and Meier, 1958) and differences in survival
distributions were evaluated by the generalized Wilcoxon test
(Gehan, 1965). Prognostic values of p16, Rb, p16/Rb and p53
proteins were estimated by univariate and multivariate analyses
using Cox’s proportional hazards general linear model (Harrell,
1986). The significance level chosen was P < 0.05, and all tests
were two-sided. These computations were performed with the
SAS program package (Harrell, 1986).
Table 2 Univariate and multivariate analyses of potential prognostic factors
in resected NSCLCs
Hazards 95% confidence
Characteristics ratio interval Pa
A. Univariate analysis
Age 0.99 0.95–1.03 0.6
Gender 2.13 0.73–6.24 0.2
Histological typeb 1.34 0.58–3.14 0.5
pStage 1.71 1.13–2.58 0.01
Chemotherapy 0.76 0.33–1.75 0.5
p16 0.88 0.35–2.25 0.8
Rb 0.88 0.21–3.79 0.9
p16/Rb 0.86 0.36–2.03 0.7
p53 2.15 0.96–4.81 0.06
B. Multivariate analysis
pStage 2.56 1.03–6.41 0.03
p53 1.92 0.85–4.33 0.1
aAnalysed by Cox’s proportional hazards general linear model. bSquamous
cell carcinoma vs non-squamous cell carcinoma.
AB
CD
Figure 1 Immunostaining patterns for p16 (A, B) and Rb (C, D) proteins in primary NSCLCs. Representative p16+ adenocarcinoma shows strong and
homogeneous nuclear staining of p16 protein in tumour cells (A). In contrast, p16– squamous cell carcinoma shows no nuclear staining of p16 protein in tumour
cells (B). Representative Rb+ squamous cell carcinoma displays intense nuclear staining of Rb protein in tumour cells (C). Rb-adenocarcinoma displays no
nuclear staining of Rb protein in tumor cells (D). Note that admixed stromal cells (arrows) show distinct nuclear staining of p16 and Rb proteins in all specimens,
which provide positive internal controls for both proteins. A–D, ´400. Scale bar = 20 mmPrognostic value of p16, Rb and p53 in NSCLCs 699
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RESULTS
Of 111 NSCLCs analysed in the previous study (Kinoshita et al,
1996), 76 tumours were studied to determine the prognostic
importance of p16 protein status alone or in combination with Rb
protein status (p16/Rb) in the present study. Typical immuno-
staining for p16 and Rb proteins in NSCLCs is shown in Figure 1.
Twenty-two (29%) NSCLC tumours lacked p16 protein expres-
sion, and eight (11%) lacked Rb protein. Thus, 30 (39%) NSCLCs
had a loss of either p16 or Rb protein, while 30 (39%) showed
positive (altered) p53 protein expression (Table 1).
Survival of patients with p16– and p16+ tumours was very
similar, and not significantly different (5-year survival rates 67%
and 72% respectively, P = 0.8) (Figure 2A). Survival of patients
with Rb– tumours was not significantly different from survival of
patients with Rb+ tumours (5-year survival rates 42% and 69%
respectively, P = 0.9) (Figure 2B). Finally, survival of patients with
tumours lacking either p16 or Rb protein (p16– or Rb–; p16/Rb–)
was almost the same as that of patients with tumours retaining both
p16 and Rb proteins (p16+ and Rb+; p16/Rb+) (5-year survival
rates 67% and 68% respectively, P = 0.7) (Figure 2C). In contrast,
survival of patients with p53+ (altered) tumours tended to be
shorter than that of patients with p53– (unaltered) tumours (5-year
survival rates 56% and 78% respectively, P = 0.06) (Figure 2D). As
shown in Table 1, there was no statistically significant difference
between the p16+ and p16– groups and between p16/Rb+ and
p16/Rb– groups in this cohort with regard to the distributions of
other characteristics, including age, gender, smoking, disease stage
and post-surgical chemotherapy given. In particular, the data
clearly indicated that the two groups were well balanced for disease
stage, a previously identified prognostic factor. However, p16
protein was lost more frequently in adenocarcinomas and large-cell
carcinomas than in squamous cell carcinomas (P = 0.01). p16/Rb
protein status tended to be altered more often in adenocarcinomas
and large-cell carcinomas than in squamous cell carcinomas (P =
0.06), but was significantly frequently altered in p53+ tumours
compared to p53– tumours (P = 0.046). Inversely, p53– tumours
significantly frequently showed unaltered p16/Rb protein status.
Statistical significance of potential prognostic factors was deter-
mined by univariate analysis (Table 2A). p16, Rb and p16/Rb
proteins were not significant prognostic factors, although disease
stage was. Altered p53 protein status tended to be a negative prog-
nostic factor (P = 0.06). In the multivariate analysis, pStage was a
significant prognostic factor to confirm the reliability of this cohort
of potentially curatively resected NSCLCs, but altered p53 protein
status was not a significant prognostic factor (Table 2B).
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Figure 2 Kaplan–Meier survival curves of patients with resected NSCLCs. Survival curves of NSCLC patients are stratified by p16 protein (A), Rb protein (B),
p16/Rb protein (p16 protein status in combination with Rb protein status: p16/Rb–, lacking either p16 or Rb protein; p16/Rb+, retaining both p16 and Rb
proteins) (C), or p53 protein (D)700 F Hommura et al
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DISCUSSION
The present study demonstrated that expression of p16, Rb and
p16/Rb in NSCLCs was not associated with survival, and hence of
no prognostic value in patients with curatively resected NSCLCs.
In contrast, altered p53 protein expression tended to be associated
with shorter survival and to be a negative prognostic factor in the
present cohort of NSCLCs. p16 and Rb proteins have been shown
to be involved in a single regulatory pathway of the cell cycle and
tumour suppression (Serrano et al, 1993; Lukas et al, 1995), and to
be reciprocally lost in various cancers, including NSCLCs
(Okamoto et al, 1994; Otterson et al, 1994; Tam et al, 1994;
Geradts et al, 1995; Kelley et al, 1995; Shapiro et al, 1995).
Betticher et al (1997) reported that patients with altered Rb expres-
sion in their tumours, irrespective of the p16 and cyclin D1 status,
tended to have shortened event-free survival for resected NSCLCs.
These data suggested that it would be interesting to analyse losses
of both p16 and Rb proteins, and to correlate these findings with
the clinical outcome of NSCLC patients. In this regard, we investi-
gated prognostic values of losses of both proteins in patients with
resected NSCLCs in this study.
Kelley et al (1995) reported that only the cell lines established
from stage III and IV NSCLCs had homozygous deletion of the
p16 gene, and that the survival of patients having cells with and
without the homozygous deletion did not exhibit any significant
difference. On the other hand, Kratzke et al (1996) studied p16
protein expression in a cohort of resected NSCLCs by immuno-
histochemistry using formalin-fixed paraffin-embedded speci-
mens, and reported that loss of p16 protein was associated with
shorter survivals, and was a negative prognostic factor. A study by
Taga et al (1997) also showed the association of p16 protein loss
demonstrated by immunohistochemistry with shorter survivals,
but did not show its statistical significance as a prognostic factor.
The results of the latter two studies on the relationship between the
loss of p16 protein and survival and prognosis of NSCLC patients
are not in agreement with ours. This discordance may be attributed
to the difference of fixation and preservation of materials; we used
fresh, rapidly frozen tissues fixed in methanol, but the other two
studies used archived formalin-fixed paraffin-embedded tissues.
p16 is considered to be highly susceptible to chemical damage,
depending on the condition of the fixation and/or preservation of
archived tissues (Geradts et al, 1995). In addition, the antibodies
against p16 protein used and the criteria for scoring the presence or
absence of p16 protein were different among studies, and may
have caused the discordance of the results. Alternatively, the rela-
tively small number of patients analysed in the present study might
be the reason that no association of p16 and p16/Rb protein status
with clinical outcome was found. However, the present cohort was
thought to be suitable for the analysis of clinical outcome in
patients with NSCLCs, since disease stage and pN classification
(data not shown) were statistically significant prognostic factors
associated with survival, as expected. Moreover, survival curves of
patients with p16+ and p16– tumours were very similar. Likewise,
survival curves of patients with p16/Rb+ and p16/Rb– tumours
were very close to each other, suggesting that the lack of associa-
tion of p16 and p16/Rb protein status with survival was not due to
the relatively small number of patients analysed. Taken together,
these findings indicate the reliability of the present results on p16
and p16/Rb protein status in relation to survival and prognosis.
For Rb protein, the present results on the relationship between
Rb protein status and clinical outcome are consistent with those of
our previous study (Dosaka-Akita et al, 1997), in which we
reported that loss of Rb protein was not a prognostic factor for
overall NSCLCs. Loss of only one or few cell cycle regulators
functioning at the G1 checkpoint, such as p16 and Rb proteins,
may not have a profound influence on the clinical outcome of
resected NSCLCs. Multiple factors regulating the G1/S transition,
including cyclins D1 and E, cdk4 and cdk6, p27/KIP1 and p53
proteins as well as p16 and Rb proteins, may be involved in the
clinical progression and outcome of NSCLCs in a complex manner
(Quinlan et al, 1992; Horio et al, 1993; Mitsudomi et al, 1993; Xu
et al, 1994, 1996; Fujino et al, 1995; Kelley et al, 1995; Kratzke et
al, 1996; Nishio et al, 1996, 1997; Dosaka-Akita et al, 1997; Taga
et al, 1997; Yatabe et al, 1998). It has been considered that
NSCLCs are very heterogeneous both biologically and clinically
because: (1) genetic alterations, including those of tumour
suppressor genes and oncogenes, in NSCLCs are relatively
diverse, and (2) each alteration is less frequent and specific to
NSCLCs compared to genetic alterations in other types of cancer
(Minna et al, 1997). Hence, molecular prognostic markers have
not clearly emerged for NSCLCs yet (Moore and Lee, 1996).
However, determination of alterations of multiple factors involved
in more than one cell cycle regulatory and tumour suppressive
pathway may provide increased information regarding survival
and prognosis (Dosaka-Akita et al, 1997).
In conclusion, the presence or absence of expression of p16, Rb
and p16/Rb proteins did not predict the survival and prognosis in
the present cohort of patients with potentially curatively resected
NSCLCs. However, further studies are needed to determine the
prognostic importance of the loss of p16 and p16/Rb proteins in
combination with other factors regulating the G1/S transition.
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